Shah Sachin J, Barish Peter N, Prasad Priya A, Kistler Amy, Neff Norma, Kamm Jack, Li Lucy M, Chiu Charles Y, Babik Jennifer M, Fang Margaret C, Abe-Jones Yumiko, Alipanah Narges, Alvarez Francisco N, Botvinnik Olga Borisovna, Castaneda Gloria, Dadasovich Rand M, Davis Jennifer, Deng Xianding, DeRisi Joseph L, Detweiler Angela M, Federman Scot, Haliburton John, Hao Samantha, Kerkhoff Andrew D, Kumar G Renuka, Malcolm Katherine B, Mann Sabrina A, Martinez Sandra, Mary Rupa K, Mick Eran, Mwakibete Lusajo, Najafi Nader, Peluso Michael J, Phelps Maira, Pisco Angela Oliveira, Ratnasiri Kalani, Rubio Luis A, Sellas Anna, Sherwood Kyla D, Sheu Jonathan, Spottiswoode Natasha, Tan Michelle, Yu Guixia, Kangelaris Kirsten Neudoerffer, Langelier Charles
Division of Hospital Medicine, University of California, San Francisco, CA, USA.
Chan Zuckerberg Biohub, San Francisco, CA, USA.
EClinicalMedicine. 2020 Oct;27:100518. doi: 10.1016/j.eclinm.2020.100518. Epub 2020 Aug 26.
Most data on the clinical presentation, diagnostics, and outcomes of patients with COVID-19 have been presented as case series without comparison to patients with other acute respiratory illnesses.
We examined emergency department patients between February 3 and March 31, 2020 with an acute respiratory illness who were tested for SARS-CoV-2. We determined COVID-19 status by PCR and metagenomic next generation sequencing (mNGS). We compared clinical presentation, diagnostics, treatment, and outcomes.
Among 316 patients, 33 tested positive for SARS-CoV-2; 31 without COVID-19 tested positive for another respiratory virus. Among patients with additional viral testing (27/33), no SARS-CoV-2 co-infections were identified. Compared to those who tested negative, patients with COVID-19 reported longer symptoms duration (median 7d vs. 3d, < 0.001). Patients with COVID-19 were more often hospitalized (79% vs. 56%, = 0.014). When hospitalized, patients with COVID-19 had longer hospitalizations (median 10.7d vs. 4.7d, < 0.001) and more often developed ARDS (23% vs. 3%, < 0.001). Most comorbidities, medications, symptoms, vital signs, laboratories, treatments, and outcomes did not differ by COVID-19 status.
While we found differences in clinical features of COVID-19 compared to other acute respiratory illnesses, there was significant overlap in presentation and comorbidities. Patients with COVID-19 were more likely to be admitted to the hospital, have longer hospitalizations and develop ARDS, and were unlikely to have co-existent viral infections.
National Center for Advancing Translational Sciences, National Heart Lung Blood Institute, National Institute of Allergy and Infectious Diseases, Chan Zuckerberg Biohub, Chan Zuckerberg Initiative.
关于新型冠状病毒肺炎(COVID-19)患者的临床表现、诊断方法及预后的大多数数据均以病例系列形式呈现,未与其他急性呼吸道疾病患者进行比较。
我们对2020年2月3日至3月31日期间因急性呼吸道疾病到急诊科就诊且接受了严重急性呼吸综合征冠状病毒2(SARS-CoV-2)检测的患者进行了研究。我们通过聚合酶链反应(PCR)和宏基因组下一代测序(mNGS)确定COVID-19状态。我们比较了临床表现、诊断方法、治疗及预后。
在316例患者中,33例SARS-CoV-2检测呈阳性;31例非COVID-19患者的另一种呼吸道病毒检测呈阳性。在进行了额外病毒检测的患者中(27/33),未发现SARS-CoV-2合并感染。与检测呈阴性的患者相比,COVID-19患者报告的症状持续时间更长(中位数7天对3天,<0.001)。COVID-19患者住院的可能性更高(79%对56%,P = 0.014)。住院时,COVID-19患者的住院时间更长(中位数10.7天对4.7天,<0.001),发生急性呼吸窘迫综合征(ARDS)的频率更高(23%对3%,<0.001)。大多数合并症、用药情况、症状、生命体征、实验室检查结果、治疗方法及预后在COVID-19状态不同的患者之间并无差异。
虽然我们发现COVID-19与其他急性呼吸道疾病在临床特征上存在差异,但在临床表现和合并症方面有显著重叠。COVID-19患者更有可能住院、住院时间更长且发生ARDS,并且不太可能存在合并病毒感染。
美国国立转化医学推进中心、美国国立心肺血液研究所、美国国立过敏与传染病研究所、陈·扎克伯格生物中心、陈·扎克伯格倡议。